491 completed, 104 unknown, 65 terminated, 61 recruiting. 273 Not applicable, 134 Phase 4, 95 Phase 3, 81 Phase 2, 56 Phase 1.
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children Urgent PC - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | Chi Dang Hornik | 50 | 2027-04-01 | 2026-06-17 |
| Peroneal Neuromodulation vs Pelvic Floor Exercises in OAB Transcutaneous Peroneal Electrical Neuromodulation, Pelvic Floor Exercise - Overactive Bladder (OAB), Neuromodulation | Not applicable | Not yet recruiting | Marmara University | 60 | 2026-12-01 | 2026-08-26 |
| Long-Term Effectiveness and Safety of Sacral Neuromodulation With InterStim for Lower Urinary Tract Dysfunction InterStim™ Sacral Neuromodulation System II - X - Overactive Bladder (OAB), Urgency Urinary Incontinence | Not yet recruiting | Fundación Santa Fe de Bogota | 1700 | 2026-12-01 | 2026-10-02 | |
| Transcranial Direct Current Stimulation for Neurogenic Overactive Bladder Symptoms Among People With Stroke Active transcranial direct current stimulation (tDCS), Sham transcranial direct current stimulation (tDCS), Pelvic floor muscle training (PFMT) - Stroke, Neurogenic Overactive Bladder | Not applicable | Not yet recruiting | The Hong Kong Polytechnic University | 60 | 2026-11-10 | 2026-10-26 |
| Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease mirabegron, Exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 4 | Not yet recruiting | VA Office of Research and Development | 146 | 2026-11-09 | 2026-10-27 |
| Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder Mirabegron (beta3-adrenoceptor agonist) - Overactive Bladder (OAB) | Not yet recruiting | Bagcilar Training and Research Hospital | 115 | 2026-11-01 | 2026-10-05 | |
| Impact of Transcutaneous Electrical Nerve Stimulation on the Autonomic Nervous System in the Treatment of Overactive Bladder heart rate variability assement - Overactive Bladder (OAB) | Not applicable | Not yet recruiting | Centre Hospitalier de Roubaix | 70 | 2026-10-01 | 2026-08-24 |
| Parasacral TENS Project Parasacral transcutaneous electric nerve stimulation (TENS), Oxybutynin - Overactive Bladder (OAB), Lower Urinary Tract Dysfunction | Not applicable | Not yet recruiting | University of Virginia | 60 | 2026-09-30 | 2026-10-23 |
| Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release - Overactive Bladder (OAB) | Phase 3 | Not yet recruiting | NinaMED Pty Ltd | 290 | 2026-09-10 | 2026-08-24 |
| Efficacy of Transcutaneous Electrical Stimulation Therapy in the Treatment of Overactive Bladder Developing After Stroke posterior tibial nerve stimulation, PTNS - Stroke, Overactive Bladder (OAB) | Not applicable | Not yet recruiting | Kutahya Health Sciences University | 50 | 2026-09-01 | 2026-07-31 |
| Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation - Cervical Carcinoma, Endometrial Carcinoma | Not applicable | Recruiting | Mayo Clinic | 44 | 2026-08-20 | 2026-08-31 |
| Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Ambulatory Transcutaneous Tibial Nerve Stimulation, Conventional Clinic-Based Transcutaneous Tibial Nerve Stimulation - Overactive Bladder (OAB), Urinary Urgency | Not applicable | Recruiting | SEZGIN | 60 | 2026-08-15 | 2026-09-18 |
| RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham - Overactive Bladder (OAB) | Phase 2 | Recruiting | Vensica Therapeutics Ltd. | 210 | 2026-08-14 | 2026-10-16 |
| Treatment Efficacy for Overactive Bladder: Comparing Education, Biofeedback, and Nerve Stimulation Behavioral, Enraf-Nonius EMG-Biofeedback Unit (Biofeedback only), Enraf-Nonius EMG-Biofeedback Unit (Biofeedback + Electrical Stimulation) - Urinary Bladder, Overactive, Urinary Incontinence, Urge | Not applicable | Not yet recruiting | Far Eastern Memorial Hospital | 201 | 2026-08-03 | 2026-08-04 |
| Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women Low-Intensity Extracorporeal Shock Wave Therapy, Sham Low-Intensity Extracorporeal Shock Wave Therapy - Urinary Bladder, Overactive | Not applicable | Not yet recruiting | Al-Azhar University | 40 | 2026-08-01 | 2026-07-31 |
| Does Use of a Pre-Procedure Educational Video for Urodynamic Testing Reduces Anxiety? video - Urinary Incontinence, Urinary Bladder Overactive | Not applicable | Recruiting | Yair Daykan | 60 | 2026-08-01 | 2026-08-04 |
| Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms Macrobid® Capsules 100 mg, Standard Medical Care (SMC) - Overactive Bladder | Early Phase 1 | Recruiting | The Cleveland Clinic | 260 | 2026-07-31 | 2026-08-03 |
| Pretibial TENS for Pain and Anxiety During Intravesical OnabotulinumtoxinA Injection Active Pretibial TENS, Sham Pretibial TENS - Overactive Bladder (OAB), Botulinum Toxin Injection | Not applicable | Not yet recruiting | Başakşehir Çam & Sakura City Hospital | 68 | 2026-07-20 | 2026-07-16 |
| SGLT-2 Inhibitors and Lower Urinary Tract Symptoms No Intervention: Observational Cohort - SGLT2 Inhibitors, Lower Urinary Track Symptoms | Active not recruiting | Marmara University | 40 | 2026-07-01 | 2026-07-21 | |
| Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study Solifencin, Mirabegron - Overactive Bladder (OAB) | Phase 4 | Not yet recruiting | Universidade do Porto | 208 | 2026-07-01 | 2026-07-17 |
Showing 20 of 802. Sign in to see all of them.
Urinary Incontinence (136) · Urinary Incontinence, Urge (131) · Lower Urinary Tract Symptoms (46) · Nocturia (24) · Urinary Bladder, Neurogenic (24) · Prostatic Hyperplasia (23) · Multiple Sclerosis (21) · Urinary Incontinence, Stress (18) · Urologic Diseases (16) · Parkinson Disease (13) · Spinal Cord Injuries (13) · Urinary Tract Infections (12) · Cystitis, Interstitial (10) · Fecal Incontinence (10)
Pathological Conditions, Signs and Symptoms (802) · Urogenital Diseases (802) · Female Urogenital Diseases and Pregnancy Complications (801) · Male Urogenital Diseases (801) · Signs and Symptoms (801) · Female Urogenital Diseases (800) · Urological Manifestations (800) · Urinary Bladder Diseases (793) · Urologic Diseases (786) · Lower Urinary Tract Symptoms (756) · Urination Disorders (239) · Urinary Incontinence (97) · Nervous System Diseases (79) · Neurologic Manifestations (39) · Genital Diseases (34)
Solifenacin Succinate (88) · mirabegron (78) · Botulinum Toxins, Type A (61) · Tolterodine Tartrate (57) · fesoterodine (37) · oxybutynin (22) · darifenacin (18) · Transcutaneous Electric Nerve Stimulation (14) · Tamsulosin (12) · trospium chloride (11) · propiverine (10) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (9) · Saline Solution (9) · Behavior Therapy (8) · imidafenacin (8)
Astellas Pharma Inc (42) · Pfizer (29) · Allergan (24) · Bayer (11) · National Taiwan University Hospital (10) · Astellas Pharma Europe B.V. (9) · Pamukkale University (9) · GlaxoSmithKline (8) · MedtronicNeuro (8) · Samsung Medical Center (8) · Urovant Sciences GmbH (8) · Buddhist Tzu Chi General Hospital (7) · Mansoura University (7) · Novartis (7) · Seoul National University Hospital (7)
United States (318) · South Korea (62) · Turkey (Türkiye) (61) · Canada (55) · United Kingdom (54) · France (51) · Germany (44) · Belgium (43) · Poland (40) · Taiwan (39) · Netherlands (38) · Czechia (37) · Spain (34) · Denmark (31) · Italy (30)
Kyu-Sung Lee, Ph.D (8) · Rose Khavari, MD (7) · Hann-Chorng Kuo, M.D. (6) · Ho-Hsiung Lin, PhD (5) · Kenneth Peters, MD (5) · Seyda Toprak Celenay (4) · Elizabeth Camille Vaughan, MD MS (3)
PMID 37160401, PMID 37811598, PMID 17049716, PMID 35881009, PMID 12559262, PMID 19941278, PMID 12811491, PMID 24246044, PMID 32791124, PMID 36148895, PMID 11857671, PMID 16406907, PMID 18499184, PMID 20035977, PMID 21293089, PMID 22258963, PMID 22464310, PMID 23036134, PMID 23218404, PMID 23608668, PMID 24754838, PMID 25288099, PMID 25623739, PMID 26231052, PMID 26337427, PMID 26423260, PMID 26573101, PMID 26663726, PMID 27350947, PMID 28754926, PMID 29071144, PMID 29692690, PMID 31039103, PMID 32665528, PMID 33429090, PMID 33955921, PMID 35400537, PMID 41944009, PMID 10027879, PMID 10188996, PMID 10435146, PMID 10699609, PMID 10767443, PMID 10775736, PMID 10797303, PMID 1114545, PMID 11176525, PMID 11412210, PMID 11874310, PMID 12007519
2015 (4), 2008 (2), 2014 (2), 2017 (2), 2018 (2), U01DK097772 (2), U01DK097779 (2), U01DK097780 (2), U01DK099879 (2), U01DK099932 (2), U01DK100011 (2), U01DK100017 (2), 2009 (1), 2016 (1), 2019 (1)